In 2022, Spain had a mortality rate from ischemic heart disease of around ***** deaths per 100,000 inhabitants. By autonomous community, Ceuta had the highest number of deaths from ischemic heart diseases per 100,000 population that year, amounting to ** deaths per hundred thousand inhabitants. Melilla followed, with approximately ** fatalities per 100,000 people.

In 2022, the number of heart failure cases registered in Spain reached around *******, up from approximately ******* cases reported a year prior. The number of heart failure cases in the country showed an overall increasing trend during the period analyzed. As of the last year featured, more than ****** people died from heart failure in Spain, of which the majority were women.

The number of deaths due to heart failure in Spain fluctuated within the period depicted. The figure achieved its highest value in 2008, reaching over ****** people, while the lowest value amounted to approximately ****** deaths resulting from heart failure in 2010. As of 2022, around ****** deaths in the country were attributed to this medical condition. Most deaths due to heart failure in Spain correspond to women.

Spain ES: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 6.400 NA in 2016. This records a decrease from the previous number of 6.500 NA for 2015. Spain ES: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 6.600 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 8.000 NA in 2000 and a record low of 6.400 NA in 2016. Spain ES: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Spain – Table ES.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

IntroductionAtherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event.MethodologyRetrospective observational study of electronic medical records of patients from the BIG-PAC® database (7 integrated health areas of 7 Autonomous Communities; n = 1.8 million). Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up.ResultsA total of 26,976 patients with an ASCVD episode were identified during the recruitment period; Out of them, 6,798 had a recurrent event during the follow-up period and 2,414 died. The average costs per patient were €11,171 during the first year and €9,944 during the second year.DiscussionPatients with ASCVD represent a significant economic burden for the health system and for society. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount. Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do).

In 2021, more than 14 thousand people died from hypertensive heart disease in Spain. The most affected age groups by these heart conditions included the oldest segments of the population from 85 to more than 95 years, especially those between 90 and 94 years, which registered about four thousand deaths due to hypertensive heart diseases in the European country by that time.

In 2021, the annual number of deaths caused by hypertensive heart disease in Spain amounted to approximately **** thousand cases, a decrease compared to the figure reported a year prior. Women accounted for nearly ** percent of the recorded deaths from hypertensive heart disease in Spain, reaching more than *** thousand fatal cases. Meanwhile, the number of men that reportedly died surpassed *** thousand people.

BackgroundAtherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs. In Spain, the evidence about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study. The aim of this study is to describe the demographic and clinical characteristics, comorbidities, and concomitant medication of patients with ASCVD and hypercholesterolemia and of patients with familial hypercholesterolemia (FH). The use of healthcare resources and costs associated to the management of these diseases after their diagnosis were also considered.MethodsThis is an observational and retrospective study, based on the BIG-PAC® database, which includes the electronic medical registries (EMRs) of 1.8 million people from 7 Autonomous Communities in Spain (including public primary care centers and hospitals). The study includes patients who had a new or recurrent episode of ASCVD during the recruitment period (from 01/01/2017 to 31/12/2018). The index date will be defined as the date of the ASCVD event, and the follow-up period will be 24 months. According to their first diagnosis in the database, patients will be classified as ASCVD (5 groups: stable/unstable angina, acute myocardial infarction, ischemic stroke, transient ischemic attack, and peripheral arterial disease) or FH.DiscussionThis study aims to analyze the treatment patterns and use of healthcare resources of ASCVD and FH in Spain. The prevalence of these disorders will also be estimated. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.

Snapshot img

Cardiac Rehabilitation Market Size 2024-2028

The cardiac rehabilitation market size is forecast to increase by USD 1.97 billion, at a CAGR of 6.59% between 2023 and 2028.

The market is driven by the high prevalence of cardiovascular diseases, making it a significant market with immense potential. The increasing burden of cardiovascular diseases worldwide necessitates the need for effective rehabilitation programs to improve patient outcomes and reduce healthcare costs. However, this market faces challenges, including the rising adoption of telerehabilitation and cost barriers. Telerehabilitation, a remote form of cardiac rehabilitation, is gaining popularity due to its convenience and accessibility. Patients can participate in rehabilitation programs from the comfort of their homes, reducing travel time and costs. This trend is expected to increase as technology advances and telehealth becomes more accessible.
However, it also poses challenges, such as ensuring patient engagement and adherence to the program, and addressing the need for proper equipment and technology. Cost barriers are another significant challenge in the market. Despite the proven benefits of cardiac rehabilitation, many patients do not participate due to the high costs associated with traditional in-person programs. This issue is further compounded by the lack of insurance coverage and reimbursement policies for these programs. To address this challenge, companies can explore innovative pricing models, such as pay-per-use or subscription-based pricing, and collaborate with insurance providers to increase coverage and reimbursement for cardiac rehabilitation services.
By addressing these challenges, companies can capitalize on the growing demand for cardiac rehabilitation services and improve patient outcomes while reducing healthcare costs.

What will be the Size of the Cardiac Rehabilitation Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample

The market continues to evolve, driven by the ongoing need for secondary prevention and improved patient outcomes. This dynamic market encompasses various sectors, including lipid profile monitoring, patient compliance, exercise prescription, and telehealth platforms. These elements are integral to effective cardiac rehabilitation programs, which aim to optimize exercise intensity and physical activity guidelines for individuals with cardiac conditions. Lifestyle modification plays a crucial role in cardiac rehabilitation, with a focus on managing diabetes, metabolic syndrome, angina pectoris, and other related conditions. Telehealth platforms facilitate remote patient monitoring, enabling continuous assessment of heart function, cardiac output, ejection fraction, and blood pressure.

Psychological support and patient education are also essential components, addressing the emotional and informational needs of patients undergoing rehabilitation. Remote patient monitoring, including left ventricular function assessment, holter monitoring, and stress testing protocols, allows for disease progression monitoring and risk stratification. Graded exercise testing and recovery monitoring are essential for optimizing exercise prescription and ensuring safe and effective rehabilitation programs. Pulmonary rehabilitation and heart failure management are additional applications that contribute to the market's ongoing growth and development. The integration of technology, such as VO2 max assessment and echocardiography results, further enhances the capabilities of cardiac rehabilitation programs.

The market's continuous dynamism reflects the evolving needs of patients and the advancements in medical technology, ensuring that cardiac rehabilitation remains a vital component of healthcare services.

How is this Cardiac Rehabilitation Industry segmented?

The cardiac rehabilitation industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Rehab centers
  Hospitals
  Clinics
  Others


Type

  Phase I
  Phase II
  Phase III


Technology Specificity

  Wearable Devices
  Tele-Rehabilitation
  Mobile Apps


Application

  Coronary Artery Disease
  Heart Failure
  Post-Surgery Recovery


Geography

  North America

    US
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  Middle East and Africa

    UAE


  APAC

    Australia
    China
    India
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By End-user Insights

The rehab centers segment is estimated to witness significant growth during the forecast period.

Cardiac rehabilitation refers t

In 2022, the number of deaths due to hypertensive heart diseases in Spain reached around ****** deceases, up from around ****** casualties reported a year earlier. The annual death toll caused by hypertensive heart diseases showed an overall increasing trend in the European country since 2005, when more than ***** people died from these conditions. In the last year depicted, approximately ****** individuals died as a result of heart failure in Spain.

In 2022, Spain had a mortality rate from chronic liver disease of around eight deaths per 100,000 inhabitants. The autonomous communities with the highest number of deaths from chronic liver disease were Melilla and Asturias, with approximately **** deaths and **** fatalities per 100,000 population due to chronic liver disease. That year, Melilla also had one of the highest mortality rate from ischemic heart disease per 100,000 people in the country.

AimsTo describe the main characteristics of patients recently diagnosed with DM regarding cardiovascular risk factors and diabetes-related complications, compare possible differences according to sex and age group, and examine healthy lifestyle behaviors such as adherence to the Mediterranean diet and physical activity and their associated factors.MethodsA cross-sectional, multicenter, observational study of 681 patients aged >30 years diagnosed with diabetes mellitus in the previous 4 years was performed. The patients were treated in primary care centers in Madrid (Spain). The variables were obtained from their electronic medical records, physical examination, complete analysis, and lifestyle questionnaires.ResultsThe main comorbidities were: hypercholesterolemia (64.4%; 95% CI, 60.6–68.2), hypertension (55.2%; 95% CI, 51.3–59.1), obesity (58.9%; 95% CI, 55.2–62.6), metabolic syndrome (58.5%; 95% CI, 54.6–62.5); and hypertriglyceridemia (25.3%; 95% CI, 21.9–28.7). Despite being newly diagnosed, 7.6% (95% CI, 5.4–9.8) had microalbuminuria, and 10.3% (95% CI, 8.0–12.6) cardiovascular disease. The main unhealthy lifestyles were: low physical activity (52%; 95% CI, 48.1–55.9), alcohol consumption (47.7%; 95% CI, 44.0–51.5) and smoking (19.2%; 95% CI, 16.2–22.3). Compared with men, women had more morbid obesity (9.7% vs 4.6%, p = .014), worse lipid profile (total cholesterol: 184 (IQR, 158–207) vs. 165 (IQR, 144–192), p < .01), less treatment with metformin (74.8% vs. 84.4%, p < .01) and antiplatelet agents (8.1% vs.18.6%, p < .01), but women had fewer comorbidities. Patients with a high educational level (OR = 1.90, 95% CI, 1.28–2.81)) and those >60 years (OR = 1.49; 95% CI, 1.01–2.21) were more adherent to the Mediterranean diet, and the older ones did less intense exercise (OR = 0.34, 95% CI, 0.16–0.75). Normal blood pressure was associated with Mediterranean diet (OR = 1.52; 95% CI, 1.05–2.21) and high physical activity (OR = 4.03; 95% CI, 1.69–9.61); and body mass index was inversely associated with physical activity (OR = 0.92; 95% CI, 0.85–0.99).ConclusionsPatients newly diagnosed with diabetes mellitus may also have crucial cardiovascular risk factors and comorbidities at the onset of the disease. However, patients with a healthy lifestyle were more likely to have a normal blood pressure and a lower body mass index.